Scinovex
reviewTop 1% cited

Lipid Metabolism and Liver Inflammation. II. Fatty liver disease and fatty acid oxidation

Janardan K. ReddyM. Sambasiva Rao

Abstract

Fatty liver disease (FLD), whether it is alcoholic FLD (AFLD) or nonalcoholic FLD (NAFLD), encompasses a morphological spectrum consisting of hepatic steatosis (fatty liver) and steatohepatitis. FLD has the inherent propensity to progress toward the development of cirrhosis and hepatocellular carcinoma. It is generally difficult to distinguish AFLD from NAFLD on morphological grounds alone despite the distinctions implied by these etiological designations. The indistinguishable spectrum of histological features of both AFLD and NAFLD suggests a possible convergence of pathogenetic mechanisms at some critical juncture that enables the progression of steatohepatitis toward cirrhosis and liver cancer. From a pathogenetic perspective, FLD may be considered a single disease with multiple etiologies. Excess energy consumption and reduced energy combustion appear to be critical events that culminate in lipid storage in the liver. Energy combustion in the liver is controlled by peroxisome proliferator-activated receptor (PPAR)-alpha-regulated mitochondrial and peroxisomal fatty acid beta-oxidation systems and the microsomal omega-oxidation system. PPAR-alpha, a receptor for peroxisome proliferators, functions as a sensor for fatty acids (lipid sensor), and ineffective PPAR-alpha sensing can lead to reduced energy burning resulting in hepatic steatosis and steatohepatitis. Delineation of the pathogenetic aspects of FLD is necessary for developing novel therapeutic strategies for this disease.

Liver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated ReceptorsDiet, Metabolism, and DiseaseSteatohepatitisFatty liverCirrhosisNonalcoholic fatty liver diseaseSteatosisAlcoholic fatty liverAlcoholic liver diseaseLipid metabolismPeroxisomeInternal medicine

MeSH terms

Fatty AcidsFatty LiverHumansInflammationLiverModels, BiologicalOxidation-ReductionLipid Metabolism

Funding

  • National Institutes of Health
Citations
850
FWCI
16.38
field-weighted impact
References
31
Percentile
99%
vs. same field & year
Citations per year
Cited by
Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease
Cellular and Molecular Life Sciences · 2018 · 1,394 citations
References
Molecular mediators of hepatic steatosis and liver injury
Journal of Clinical Investigation · 2004 · 1,814 citations
Steatohepatitis: A tale of two “hits”?
Gastroenterology · 1998 · 4,263 citations
Nonalcoholic Steatohepatitis
Mayo Clinic Proceedings · 1980 · 2,875 citations
Molecular mediators of hepatic steatosis and liver injury
Journal of Clinical Investigation · 2004 · 1,760 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Lipid Metabolism and Liver Inflammation. II. Fatty liver disease and fatty acid oxidation · Scinovex